Drug Type Small molecule drug |
Synonyms (S)-4-(2-Amino-2-carboxyethyl)imidazole, (S)-a-Amino-1H-imidazole-4-propanoic acid, (S)-alpha-amino-1H-Imidazole-4-propanoic acid + [8] |
Target |
Action activators |
Mechanism CA1 activators(Carbonic anhydrase I activators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC6H9N3O2 |
InChIKeyHNDVDQJCIGZPNO-YFKPBYRVSA-N |
CAS Registry71-00-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | L-Histidine | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fatigue | Phase 2 | United States | 01 Jan 2022 | |
Multiple Sclerosis | Phase 2 | United States | 01 Jan 2022 |
Not Applicable | - | 40 | (4 g/d histidine supplement) | vlfnehqqrk(bfmotbadzq) = pljypiskyb aneulhhmie (qsobkwtvsx, 39.0 - 68.4) | - | 07 Aug 2020 | |
12 g/d histidine supplement | vlfnehqqrk(bfmotbadzq) = vngwdzqsmb aneulhhmie (qsobkwtvsx, 34.8 - 60.9) | ||||||
Not Applicable | - | - | bwveulvisc(kqbefnqdkf) = hlwaqatpul davwdezljy (awnuubdmgo ) | - | 01 May 2003 | ||
rsoeryyjxs(qymoqauant) = bjbgdyujvb kzgtbkusft (rjsbwmemni ) View more |